Investigational drug · Phase 3
BMS-986507
Also called: BL-B01D1, Iza-bren, Izalontamab Brengitecan, BL-BO1D1
Not approved by FDA. In 51 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
51
51 still active
All registered trials
55
Any phase or sponsor naming "BMS-986507"
First trial start
2023
Apr 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMS-986507", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Solid Tumor
- Urothelial Carcinoma
- Nasopharyngeal Carcinoma
- Breast Cancer
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
- Cervical Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BMS-986507" as an intervention, largest first.
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07680790 · 850 participants (planned) · Start Sep 8, 2026 · Primary completion Dec 30, 2031
Drug: Iza-bren; Osimertinib and 3 more · For: Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Fullerton, California; La Jolla, California · 205 sites in all
- A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)Pivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06838273 · 724 participants · Start Feb 24, 2025 · Primary completion Dec 2028
Drug: BL-B01D1; Osimertinib and 1 more · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)Pivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06500026 · 722 participants · Start Aug 7, 2024 · Primary completion Dec 2026
Drug: BL-B01D1; Topotecan · For: Small Cell Lung Cancer
Sites: Guangzhou, China
- A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Pivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06382129 · 698 participants · Start May 17, 2024 · Primary completion Dec 2026
Drug: BL-B01D1; Docetaxel · For: Non-small Cell Lung Cancer
Sites: Beijing, China
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07100080 · 661 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 15, 2028
Drug: Iza-bren; Carboplatin and 3 more · For: Non-Small Cell Lung Cancer
Sites: Irvine, California; Orange, California; Edwards, Colorado · 187 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06926868 · 600 participants (planned) · Start Sep 11, 2025 · Primary completion Mar 13, 2028
Drug: Iza-bren; Nab-paclitaxel and 4 more · For: Breast Neoplasms
Sites: Hot Springs, Arkansas; Cerritos, California; Long Beach, California · 296 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06475300 · 570 participants (planned) · Start Jun 25, 2024 · Primary completion Jun 2027
Drug: BL-B01D1; PD-1 Monoclonal Antibody and 1 more · For: Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma; Solid Tumor
Sites: Guangzhou, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05194982 · 570 participants (planned) · Start Nov 29, 2021 · Primary completion Dec 2026
Drug: BL-B01D1 · For: Locally Advanced or Metastatic Solid Tumor
Sites: Chongqing, China; Guangzhou, China; Wuhan, China · 8 sites in all
- A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)Pivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07502300 · 562 participants (planned) · Start Jun 15, 2026 · Primary completion Dec 2029
Drug: BL-B01D1; Tislelizumab and 2 more · For: Extensive-stage Small-cell Lung Cancer
Sites: Zhengzhou, China; Shanghai, China
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)Pivotal-lookingRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07582315 · 538 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 2028
Drug: BL-B01D1; Oxaliplatin and 5 more · For: Biliary Tract Cancer
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Antibodies to watch in 2026.
Crescioli S, Kaplon H, Chenoweth A, et al. · MAbs 2026
- Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: Research Summary.
· JAMA 2026
- Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial.
Lu Z, Huang Z, Meng X, et al. · JAMA 2026
- Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.
Zhang J, Meng Y, Du Y, et al. · Ann Oncol 2026
- Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
Hong S, Zhou T, Hou X, et al. · Lancet 2026
- Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
Lan B, Shi Y, Shao X, et al. · Lancet 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.